[클리니컬 히스토리] 박셀바이오, 치료전환 재신청 키 '세포 대량증식'

ParcelBio's breakthrough in NK cell mass expansion (up to 100,000-fold) provides crucial manufacturing evidence for VAX-NK's path to commercialization, but real-world success hinges on demonstrating that laboratory-scale results translate into consistent GMP production and cost efficiency. This technology becomes pivotal for VCB-1102's regulatory resubmission, where manufacturing capability proof is now essential alongside clinical efficacy data for advanced therapy approval.